Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E
Lancet. 1984 Oct 6;2(8406):782-4. doi: 10.1016/s0140-6736(84)90706-2.
In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 injection, was not statistically significant. No side-effects and no rebound phenomenon were observed. These results suggest that SMS 201-995 may be the first somatostatin analogue suitable for the clinical management of acromegaly.
在7例肢端肥大症患者中，有6例单次皮下注射50微克一种新的八肽生长抑素类似物（SMS 201-995）后，血清生长激素（GH）从30±12纳克/毫升降至1.4±0.4（平均值±标准误）。血清GH在9小时内一直低于基础浓度。在剩余那例餐前基础血清GH非常高的患者中，SMS 201-995仅使血清GH降低了20%。注射后2小时进食高碳水化合物餐时，血浆葡萄糖浓度升高至正常范围的上限。在非糖尿病患者中，血浆葡萄糖不超过129毫克/分升。SMS 201-995注射后血浆胰高血糖素降低40%，持续7小时，但差异无统计学意义。未观察到副作用和反跳现象。这些结果表明，SMS 201-995可能是首个适用于肢端肥大症临床治疗的生长抑素类似物。
